Sexton, BioSpherix collaborate to support cell & gene therapy needs

By The Science Advisory Board staff writers

Sexton Biotechnologies is partnering with BioSpherix Medical on the final steps of downstream bioprocessing, fill-finish.

Sexton's off-the-shelf fill system, the Sexton Biotechnologies AF-500, will be combined with BioSpherix' Cytocentric isolator technology to allow for rapid process development and implementation of good manufacturing practice fill-finish.

With the AF-500, systems are ready to ship so developers can immediately begin process development of small volume fill and finish with the equipment they plan to use at clinical scale. Adding BioSpherix to the mix gives the technology the ability to operate within a fully closed environment along with the ability to control temperatures to limit risks during cryopreservation, the firms said.


Copyright © 2020 scienceboard.net
 

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?